PIPELINE

Investigational Products

Pre-Clinical
Phase I
Phase II
Phase III
NDA
Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Chronic Liver Diseases, Acute Organ Injury, Inflammatory Disorders

Drug: Undisclosed

Technology: Epigenetic Regulator

Partner: Worldwide rights held by DURECT

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Post-Operative Pain

Drug: Bupivacaine

Technology: SABER®

Partner: Worldwide rights held by DURECT

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Chronic Pain

Drug: Oxycodone

Technology: ORADUR®

Partner: Pain Therapeutics

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Chronic Pain

Drug: Hydromorphone and Oxymorphone

Technology: ORADUR®

Partner: Worldwide rights held by DURECT

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Attention Deficit Hyperactivity Disorder

Drug: Methylphenidate

Technology: ORADUR®

Partner: Orient Pharma (certain Asian countries)

*ORADUR-Methylphenidate Phase 3 is being conducted in Taiwan.

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Schizophrenia and Bipolar I Disorder

Drug: Risperidone

Technology: SABER®

Partner: Zogenix

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Post-Herpetic Neuralgia

Drug: Bupivacaine

Technology: TRANSDUR®

Partner: Impax Laboratories

Pre-ClinicalPhase IPhase IIPhase IIINDA

Proposed Indication: Ophthalmology

Drug: Undisclosed

Technology: SABER®

Partner: Santen Pharmaceutical Co.